<DOC>
<DOCNO>
EP-0004173
</DOCNO>
<TEXT>
<DATE>
19790919
</DATE>
<IPC-CLASSIFICATIONS>
C07D-239/30 A61P-37/00 A61P-31/00 C07D-239/00 C07D-487/04 A61P-31/12 C07D-487/00 A61K-31/505 A61P-37/04 <main>C07D-487/04</main> 
</IPC-CLASSIFICATIONS>
<TITLE>
2,3-dihydroimidazo (1,2-c) pyrimidines, their preparation, formulations containing them and their use as pharmaceuticals.
</TITLE>
<APPLICANT>
lilly co elius<sep>eli lilly and company<sep>eli lilly and company307, east mccarty streetindianapolis indiana 46285us<sep>eli lilly and company<sep>
</APPLICANT>
<INVENTOR>
turner william wilson<sep>turner, william wilson<sep>turner, william wilson4821 n. college avenueindianapolis indianaus<sep>turner, william wilson<sep>turner, william wilson4821 n. college avenueindianapolis indianaus<sep>
</INVENTOR>
<ABSTRACT>
compounds of the following formula are described:    wherein r is c₁-c₅ alkyl, phenyl, amino or methylmercapto,  r¹ is chloro or methylamino and r², r³ and r⁴ individually  are hydrogen, methyl or phenyl, and pharmaceutically-acceptable  acid addition salts thereof, provided that when r¹  is chloro, the compound is the hydrochloride or trifluoromethanesulfonate  salt; and the compound 7-(2-chloroethylamino)-8-nitro-2,  3-dihydroimidazo[1,  2-c]pyrimidine and its pharmaceutically-acceptable acid  addition salts.  the compounds are useful as pharmaceuticals and in  particular as anti-viral and immunoregulative agents.  
</ABSTRACT>
</TEXT>
</DOC>
